|
1000
|
Abstract/Summary
|
-
<jats:title>Abstract</jats:title><jats:p>H3 K27M-altered diffuse midline gliomas (DMGs) are highly malignant tumours that arise in the midline structures of the CNS. Most DMGs carry an H3 K27M-mutation in one of the genes encoding for histone H3. Recent studies suggested that epigenetic subgroups of DMGs can be distinguished based on alterations in the MAPK-signalling pathway, tumour localisation, mutant H3-gene, or overall survival (OS). However, as these parameters were studied individually, it is unclear how they collectively influence survival. Hence, we analysed dependencies between different parameters, to define novel epigenetic, clinically meaningful subgroups of DMGs. We collected a multifaceted cohort of 149 H3 K27M-mutant DMGs, also incorporating data of published cases. DMGs were included in the study if they could be clearly allocated to the spinal cord (<jats:italic>n</jats:italic> = 31; one patient with an additional sellar tumour), medulla (<jats:italic>n</jats:italic> = 20), pons (<jats:italic>n</jats:italic> = 64) or thalamus (<jats:italic>n</jats:italic> = 33), irrespective of further known characteristics. We then performed global genome-wide DNA methylation profiling and, for a subset, DNA sequencing and survival analyses. Unsupervised hierarchical clustering of DNA methylation data indicated two clusters of DMGs, i.e. subtypes DMG-A and DMG-B. These subtypes differed in mutational spectrum, tumour localisation, age at diagnosis and overall survival. DMG-A was enriched for DMGs with MAPK-mutations<jats:italic>,</jats:italic> medullary localisation and adult age. 13% of DMG-A had a methylated <jats:italic>MGMT</jats:italic> promoter. Contrarily, DMG-B was enriched for cases with <jats:italic>TP53</jats:italic>-mutations, <jats:italic>PDGFRA</jats:italic>-amplifications, pontine localisation and paediatric patients. In univariate analyses, the features enriched in DMG-B were associated with a poorer survival. However, all significant parameters tested were dependent on the cluster attribution, which had the largest effect on survival: DMG-A had a significantly better survival compared to DMG-B (<jats:italic>p</jats:italic> < 0.001). Hence, the subtype attribution based on two methylation clusters can be used to predict survival as it integrates different molecular and clinical parameters.</jats:p>
|
